ZYME
- Zymeworks Inc.
()
Overview
Company Summary
Zymeworks Inc. is a biopharmaceutical company that specializes in the development of multifunctional protein therapeutics. They use unique and innovative approaches to engineer and optimize therapeutic proteins with the aim of treating a variety of diseases, including cancer and autoimmune disorders.
Zymeworks' proprietary protein engineering platform, called Azymetric�, allows them to create novel drug candidates with enhanced properties and improved therapeutic outcomes. This platform enables the development of bi-specific antibodies, antibody-drug conjugates (ADCs), and other therapeutic proteins that can simultaneously act on multiple disease targets.
One of Zymeworks' key offerings is their Azymetric� Immune Cell Engagers (ICE�) platform, which is designed to harness the patient's immune system to target and destroy cancer cells selectively. This technology brings together two antibodies, one that binds to cancer cells and another that activates immune cells, producing a localized immune response against the tumor.
Zymeworks also focuses on developing ADCs, which are targeted therapies that combine antibodies with cytotoxic drugs. By precisely delivering the cytotoxic drug to cancer cells, ADCs minimize damage to healthy cells, resulting in better efficacy and reduced side effects.
In addition to their internal drug development programs, Zymeworks collaborates with pharmaceutical and biotechnology companies to leverage their protein engineering expertise and develop innovative therapies against a range of diseases.
Overall, Zymeworks Inc. is dedicated to advancing the field of protein engineering and developing transformative therapies that can potentially improve the lives of patients suffering from various diseases.